Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Shapiro

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimusJose Pablo Maroto, Gary Hudes, Janice P Dutcher, et al.
Surgical Infections|March 1, 2021
Surgical Infection Society 2020 Updated Guidelines on the Management of Complicated Skin and Soft Tissue InfectionsTherese M Duane, Jared M Huston, Morgan Collom, et al.
Cancer|October 27, 2017
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapyHagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, et al.
Annals of Surgical Oncology|January 9, 2008
An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resectionJonathan Hernandez, Sarah M Cowgill, Sam Al-Saadi, et al.
The American Journal of Gastroenterology|April 26, 2006
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's diseaseKlaus R Herrlinger, Thomas Witthoeft, Andreas Raedler, et al.
Melanoma Research|May 13, 2022
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanomaZachary Wolfe, Julie C Friedland, Sarah Ginn, et al.
American Journal of Hematology|June 5, 2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitorsCarlo Gambacorti-Passerini, Hagop M Kantarjian, Dong-Wook Kim, et al.
Journal of the American Geriatrics Society|January 31, 2022
Pilot and feasibility deployment of an advanced remote monitoring platform for COVID-19 in long-term care facilitiesJessica R Walter, Dong-Hyun Kim, Daniel Myers, et al.
British Journal of Haematology|November 6, 2015
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibTim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, et al.
Nature Chemical Biology|February 6, 2023
Programmable synthetic biomolecular condensates for cellular controlYifan Dai, Mina Farag, Dongheon Lee, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimusJose Pablo Maroto, Gary Hudes, Janice P Dutcher, et al.
Surgical Infections|March 1, 2021
Surgical Infection Society 2020 Updated Guidelines on the Management of Complicated Skin and Soft Tissue InfectionsTherese M Duane, Jared M Huston, Morgan Collom, et al.
Cancer|October 27, 2017
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapyHagop M Kantarjian, Carla M Mamolo, Carlo Gambacorti-Passerini, et al.
Annals of Surgical Oncology|January 9, 2008
An aggressive approach to extrahepatic cholangiocarcinomas is warranted: margin status does not impact survival after resectionJonathan Hernandez, Sarah M Cowgill, Sam Al-Saadi, et al.
The American Journal of Gastroenterology|April 26, 2006
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's diseaseKlaus R Herrlinger, Thomas Witthoeft, Andreas Raedler, et al.
Melanoma Research|May 13, 2022
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanomaZachary Wolfe, Julie C Friedland, Sarah Ginn, et al.
American Journal of Hematology|June 5, 2015
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitorsCarlo Gambacorti-Passerini, Hagop M Kantarjian, Dong-Wook Kim, et al.
Journal of the American Geriatrics Society|January 31, 2022
Pilot and feasibility deployment of an advanced remote monitoring platform for COVID-19 in long-term care facilitiesJessica R Walter, Dong-Hyun Kim, Daniel Myers, et al.
British Journal of Haematology|November 6, 2015
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibTim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, et al.
Nature Chemical Biology|February 6, 2023
Programmable synthetic biomolecular condensates for cellular controlYifan Dai, Mina Farag, Dongheon Lee, et al.
Pageof 6